MIRACLE-T2D Montelukast Intervention for Renal, Cardiovascular and Eye Health in Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 110 participants.
Also called NCT07685886
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 110 participants
- Registry
-
NCT07685886
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07685886. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-01 (anticipated); primary completion 2031-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- MIRACLE-T2D Montelukast Intervention for Renal, Cardiovascular and Eye Health in Type 2 Diabetes
- Acronym
- MIRACLE-T2D
- Condition
- Diabetes
- Condition
- Kidney Disease
- Condition
- Vascular Disease
- Condition
- Retinopathy
- Intervention (Drug)
- Montelukast
- Intervention (Drug)
- Placebo
- Lead sponsor
- University of Colorado, Denver
Record details
- Record id
cardio:ct-nct07685886- Content hash
6c8f49169d349d520e4aa6cedca5741b30dbf286d5e3316b44d42d9d9d471986